Lai C.-W.KUEN-YUAN CHENHung C.-S.Kuo S.-W.Chang Y.-J.MING-TSAN LINChang K.-C.MING-HSUN WU2020-03-232020-03-2320110897-7194https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955846725&doi=10.3109%2f08977194.2011.557373&partnerID=40&md5=2e9314f849f3e54b6d2c9f507262abcbhttps://scholars.lib.ntu.edu.tw/handle/123456789/477452The aim of this multicenter study was to evaluate the clinical relevance of serum vascular endothelial growth factor-D (VEGF-D) in papillary thyroid carcinoma (PTC). This prospective study consisted of 74 patients with primary PTC and 15 patients with benign thyroid nodules treated from 2008 to 2009. VEGF-D concentration was compared with patient clinicopathologic features and lymph node metastases. There was no significant difference in mean serum VEGF-D levels between the PTC and benign thyroid nodule groups. Within the PTC group, serum VEGF-D levels were significantly higher in patients with lymph node metastases than in patients without metastases (241.92 vs. 213.89 pg/ml, respectively; P = 0.035). Receiver operating characteristic curve analysis revealed that preoperative serum VEGF-D levels were predictive of lymph node metastases in the patients >45 years. Serum VEGF-D level that was correlated with the presence of cervical lymph node metastases in PTC patients might be a useful prognostic indicator. ? 2011 Informa UK, Ltd.[SDGs]SDG3vasculotropin D; adult; article; cervical lymph node; comparative study; disease marker; female; human; lymph node metastasis; major clinical study; male; priority journal; prognosis; protein blood level; protein function; receiver operating characteristic; thyroid nodule; thyroid papillary carcinoma; Adult; Carcinoma, Papillary; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; ROC Curve; Thyroid Neoplasms; Vascular Endothelial Growth Factor Djournal article10.3109/08977194.2011.557373213199512-s2.0-79955846725